Amaryl

Amaryl (developed by Sanofi) is the flagship brand name for glimepiride, a potent second- or third-generation sulfonylurea oral antihyperglycemic medication used in the treatment of type 2 diabetes mellitus. It acts primarily as an insulin secretagogue by binding to sulfonylurea receptors (SUR1) on the plasma membrane of pancreatic beta cells.

This binding closes ATP-sensitive potassium ($K_{\text{ATP}}$) channels, resulting in cell membrane depolarization, opening of voltage-gated calcium channels, calcium influx, and exocytosis of pre-formed insulin granules into the bloodstream. Relative to older sulfonylureas, glimepiride dissociates rapidly from the SUR1 receptor, which provides a lower overall incidence of severe, prolonged hypoglycemia and less hyperinsulinemic drive between meals while maintaining strong postprandial glucose control.

Primary Medical Indications

Amaryl is indicated for adult patients (aged 18 years and older) in the management of endocrine and metabolic conditions:

• Type 2 Diabetes Mellitus: As an adjunct to diet, weight management, and physical exercise to lower elevated blood glucose and reduce HbA1c levels when non-pharmacological measures alone are insufficient.

• Monotherapy: For type 2 diabetic patients where first-line metformin therapy is contraindicated or poorly tolerated.

• Dual & Triple Combination Therapy: Combined with other complementary antidiabetic agents (e.g., metformin, DPP-4 inhibitors, SGLT2 inhibitors, or thiazolidinediones) or basal/bolus insulin regimens when single-agent therapy fails to achieve glycemic targets.

Key Product Specifications & Dosing Forms

Critical Safety Guidelines & Precautions

• Hypoglycemia Risk: As an insulin secretagogue, Amaryl can cause hypoglycemia (low blood sugar), particularly if meals are skipped, delayed, or insufficient, during strenuous unaccustomed physical activity, excessive alcohol ingestion, or co-administration with other hypoglycemic drugs.

• Must Be Taken with Food: To prevent acute drops in blood glucose, Amaryl must always be taken immediately before or during a substantial meal containing complex carbohydrates.

• G6PD Deficiency Warning: Treatment with sulfonylureas in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency can lead to acute hemolytic anemia. Non-sulfonylurea alternative agents should be considered in this patient population.

• Renal & Hepatic Impairment: Clearance is reduced in severe renal or hepatic disease, raising the risk of accumulation and prolonged hypoglycemia. Initiate at 1 mg daily and titrate with caution under close blood glucose monitoring.

• Contraindications: Strictly contraindicated in patients with type 1 diabetes mellitus, diabetic ketoacidosis (DKA), diabetic coma/pre-coma, or known hypersensitivity to glimepiride, sulfonylureas, or sulfonamide derivatives.